Sponsor

Olema Pharmaceuticals, Inc.

Clinical research sponsor

Published trials6

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

6 shown

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · lead sponsor · 2025-11-03

RECRUITING

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsNCT06784193 · lead sponsor · 2024-12-16

RECRUITING

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · lead sponsor · 2023-11-16

ACTIVE_NOT_RECRUITING

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerNCT05508906 · lead sponsor · 2022-08-31

ACTIVE_NOT_RECRUITING

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsNCT05266105 · lead sponsor · 2021-12-10

ACTIVE_NOT_RECRUITING

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerNCT04505826 · lead sponsor · 2020-08-13

COMPLETED

Sponsor roles

lead sponsor6

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.